Cargando…
Distinguishing Benign from Malignant Pancreatic and Periampullary Lesions Using Combined Use of (1)H-NMR Spectroscopy and Gas Chromatography–Mass Spectrometry
Previous work demonstrated that serum metabolomics can distinguish pancreatic cancer from benign disease. However, in the clinic, non-pancreatic periampullary cancers are difficult to distinguish from pancreatic cancer. Therefore, to test the clinical utility of this technology, we determined whethe...
Autores principales: | McConnell, Yarrow J., Farshidfar, Farshad, Weljie, Aalim M., Kopciuk, Karen A., Dixon, Elijah, Ball, Chad G., Sutherland, Francis R., Vogel, Hans J., Bathe, Oliver F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372206/ https://www.ncbi.nlm.nih.gov/pubmed/28098776 http://dx.doi.org/10.3390/metabo7010003 |
Ejemplares similares
-
Serum metabolomic profile as a means to distinguish stage of colorectal cancer
por: Farshidfar, Farshad, et al.
Publicado: (2012) -
Performance of variable selection methods using stability-based selection
por: Lu, Danny, et al.
Publicado: (2017) -
A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics
por: Farshidfar, Farshad, et al.
Publicado: (2016) -
Sarcopenia and myosteatosis are accompanied by distinct biological profiles in patients with pancreatic and periampullary adenocarcinomas
por: Stretch, Cynthia, et al.
Publicado: (2018) -
Identification of prognostic inflammatory factors in colorectal liver metastases
por: Hamilton, Trevor D, et al.
Publicado: (2014)